Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Vitamin D (cholecalciferol) is scientifically validated for use in the management of psoriasis, though primarily in its topical form rather than as an oral supplement. Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes and immune dysregulation. Topical vitamin D analogs (such as calcipotriol and calcitriol) are widely used and recommended in clinical guidelines for mild to moderate plaque psoriasis. These compounds modulate keratinocyte proliferation and differentiation, and exert immunomodulatory effects by inhibiting T-cell activity and pro-inflammatory cytokine production in psoriatic lesions.

Multiple randomized controlled trials and meta-analyses have demonstrated that topical vitamin D analogs are effective and generally well tolerated, with efficacy comparable to topical corticosteroids for many patients. Systematic reviews, including a 2013 Cochrane review, found that vitamin D analogs improve psoriasis symptoms and severity scores, especially when used in combination with corticosteroids.

There is less robust evidence for oral vitamin D supplementation as a treatment for psoriasis, except in the case of patients who are deficient in vitamin D. Some small trials and case reports suggest potential benefit, but larger, well-controlled studies are lacking, and routine supplementation is not standard care for psoriasis in the absence of deficiency. In summary, vitamin D’s use, particularly in topical form, is well supported by scientific evidence for psoriasis management.

More about Vitamin D (cholecalciferol)
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by Vitamin D (cholecalciferol)

Products containing Vitamin D (cholecalciferol)